The Phase 2 trial evaluating the combination of the TPIV 200 cancer vaccine with the immune checkpoint inhibitor Imfinzi (durvalumab) in ovarian cancer patients who progressed after receiving platinum-based chemotherapy has enrolled more than half of study participants, TPIV 200 developer TapImmune announced. The company also provided updates on the Phase 2 trial evaluating TPIV 200, which received fast–track status from the U.S. Food and Drug Administration, as a maintenance therapy in ovarian cancer patients who responded to platinum-based chemotherapy. Results of the trials are expected by the second quarter of 2017 and the second half of 2018, respectively. TPIV 200 is a multi–epitope peptide vaccine targeting the folate receptor alpha, known to be over-expressed in over 90% of ovarian cancer cells. According to TapImmune, Phase 1 studies in patients with breast and ovarian cancer showed the vaccine to be safe and well–tolerated, resulting in immune responses in 20 out of 21 evaluable patients. TPIV 200 is being evaluated in a Phase 2 clinical trial, (NCT02764333), in combination with AstraZeneca’s PD-L1 antibody Imfinzi, in patients with platinum-resistant ovarian cancer.